Autoimmune blistering diseases (AIBDs), including pemphigus and pemphigoid, represent a significant clinical challenge in dermatology. Reliable epidemiological research is vital for understanding these conditions. However, a recent scoping review suggests that many population-based studies rely on unvalidated autoimmune blistering disease definitions. This reliance on administrative coding or electronic health records without verification may skew the data.

Researchers examined 92 studies covering various AIBDs. Most studies used International Classification of Diseases (ICD) codes. However, only a few performed rigorous validation. For example, in 63 pemphigoid studies, only 26 validated their cases. They typically used a mix of clinical diagnosis, histopathology, and immunofluorescence. Notably, the lack of validation was more pronounced in rarer diseases like epidermolysis bullosa acquisita (EBA).

Standardizing Autoimmune Blistering Disease Definitions

The review highlights a critical gap in current research methodologies. Among 39 pemphigus studies, only 5 validated their cases through chart reviews. Furthermore, only two out of six dermatitis herpetiformis studies used validated criteria. This lack of consistency makes it difficult to compare epidemiological findings globally. Therefore, researchers recommend improving validation practices to enhance data accuracy.

For clinicians, this means that data from large-scale health records must be interpreted with caution. Strengthening the link between clinical findings and administrative codes is necessary. In addition, future research should integrate standardized scoring systems. Consequently, this will lead to more robust and comparable evidence for managing AIBDs.

Frequently Asked Questions

Why is validation necessary for epidemiological studies of AIBDs?

Validation ensures that the diagnostic codes used in health records accurately represent the patient's condition. Without it, researchers risk misclassifying diseases, which leads to unreliable prevalence and outcome data.

What criteria are typically used to validate AIBD cases?

Valid case definitions often require a combination of two or more findings. These include characteristic clinical symptoms, histopathological evidence from skin biopsies, and positive immunofluorescence testing.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship between any party. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Zhao HJ et al. Population-Based and Routinely Collected Health Data Studies of Immunobullous Diseases: A Scoping Review. J Cutan Med Surg. 2026 Apr 25. doi: 10.1177/12034754261442933. PMID: 42033200.

Persson M, et al. Validation study of bullous pemphigoid and pemphigus vulgaris recording in routinely collected electronic primary healthcare records in England. BMJ Open. 2020;10(7):e035934. doi: 10.1136/bmjopen-2019-035934.

Schmidt E, Zillikens D. The diagnosis and treatment of autoimmune blistering skin diseases. Dtsch Arztebl Int. 2011;108(23):399-405. doi: 10.3238/arztebl.2011.0399.